600285 羚锐制药
2021/03 - 三个月
人民幣(K¥)
与去年同期
比较
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
2018/12
人民幣(K¥)
2017/12
人民幣(K¥)
营业总收入589,38820.01%2,331,5772,157,0522,053,1131,848,525
减:营业总成本479,66220.63%1,997,8011,821,3771,774,4431,611,883
    其中:营业成本132,01420.78%538,403489,927491,326496,793
               财务费用(3,616)232.44%(15,290)(2,104)7,47110,571
               资产减值损失230-561.49%(32,028)(4,434)4,33412,753
公允价值变动收益(9)-98.81%(52)(8,246)(2,137)3,035
投资收益(395)79.92%41,208(1,748)(10,678)14,893
    其中:对联营企业和合营企业的投资收益(502)-50.41%33,230(5,733)(6,224)(1,922)
营业利润112,91225.32%367,092341,447294,469266,539
利润总额112,96225.27%364,201341,284283,355263,711
减:所得税费用16,38317.35%39,81948,13937,59038,783
净利润96,57926.72%324,382293,145245,766224,928
减:非控股权益2-100.69%(1,107)(1,292)2,5027,816
股东净利润96,57726.19%325,489294,437243,264217,112

市场价值指针
每股收益 (元) *0.17025.93%0.5730.5120.4120.370
每股派息 (元) *----0.4000.3000.1500.150
每股净资产 (元) *4.2676.17%4.0733.8923.5503.671
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容